Can Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s Tomorrow Be Different? The Stock Had Decline in Shorts

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Logo

Investors sentiment decreased to 0.01 in 2018 Q3. Its down 1.06, from 1.07 in 2018Q2. It is negative, as 68 investors sold Idera Pharmaceuticals, Inc. shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 490,912 shares or 98.87% less from 43.55 million shares in 2018Q2 were reported.
Mycio Wealth Ptnrs Ltd Llc has 40,815 shares. Sphera Funds reported 0.46% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Lau Associates Ltd Com has 0.03% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA).

Since August 7, 2018, it had 6 buys, and 1 insider sale for $1.62 million activity. Shares for $31,897 were bought by Goldberg Mark Alan on Wednesday, December 19. The insider SCHAFER CAROL bought 5,000 shares worth $16,671. The insider Lim Bryant David bought $12,200. On Thursday, December 20 the insider Horobin Joanna bought $1,035. Pillar Invest Corp had sold 300,000 shares worth $1.74M on Tuesday, August 7.

The stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) registered a decrease of 22.7% in short interest. IDRA’s total short interest was 391,200 shares in January as published by FINRA. Its down 22.7% from 506,100 shares, reported previously. With 291,600 shares average volume, it will take short sellers 1 days to cover their IDRA’s short positions. The short interest to Idera Pharmaceuticals Inc’s float is 1.99%.

The stock decreased 2.64% or $0.1 during the last trading session, reaching $3.69. About 188,825 shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has declined 57.51% since January 8, 2018 and is downtrending. It has underperformed by 57.51% the S&P500.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $100.30 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 2 analysts covering Idera Pharmaceuticals (NASDAQ:IDRA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharmaceuticals had 2 analyst reports since July 16, 2018 according to SRatingsIntel. As per Monday, July 16, the company rating was maintained by Wedbush.

More notable recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: Nasdaq.com which released: “BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall – Nasdaq” on January 23, 2018, also Schaeffersresearch.com with their article: “2 Stocks Making Big Moves on Government Buzz – Schaeffers Research” published on December 14, 2018, Seekingalpha.com published: “Idera presents new data on tilsotolimod; investors unmoved, shares down 8% – Seeking Alpha” on October 19, 2018. More interesting news about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) were released by: Nasdaq.com and their article: “PRAN Gets New Lease Of Life, ADIL On Watch, GNPX Abuzz – Nasdaq” published on January 02, 2019 as well as Globenewswire.com‘s news article titled: “Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update – GlobeNewswire” with publication date: November 06, 2018.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.